By NewsDesk  @infectiousdiseasenews Seqirus announced today that it has begun to ship its portfolio of innovative seasonal influenza vaccines across the U.S. in preparation for the 2021/22 influenza...

By NewsDesk  @infectiousdiseasenews Researchers at the University of Oxford on Monday launched a Phase 1 trial to test a new vaccine against plague. Based on the ChAdOx1 adenovirus viral vector platform...

NewsDesk @bactiman63 GlaxoSmithKline today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes...

By NewsDesk  @infectiousdiseasenews Clinical-stage biotechnology company, Vivaldi Biosciences, announced positive preclinical data supporting further development of Delta-19, its combination vaccine...

By NewsDesk  @infectiousdiseasenews The Zimbabwe Ministry of Health and Child Care, with support from the World Health Organization (WHO), Gavi, the vaccine alliance and the United Nations Children’s...

By NewsDesk  @infectiousdiseasenews Specialty vaccine company, Valneva announced recently it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, announced Wednesday  the first participants have been dosed in the Phase 1/2 study of mRNA-1010, the Company’s...

By NewsDesk  @infectiousdiseasenews People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study...

By NewsDesk  @infectiousdiseasenews The International AIDS Vaccine Initiative (IAVI) was awarded €22.8 million by the European & Developing Countries Clinical Trials Partnership and the Coalition...

By NewsDesk  @infectiousdiseasenews In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre syndrome...